Boehringer, Zealand reframe diabetes pact

The companies are changing the key compound.

January 23, 2014

6:43 pm

Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.

The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.

Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.

From Our Partners

Prioritizing audience quality and contextual environment in POC marketing

Partner Content

Prioritizing audience quality and contextual environment in POC marketing

Despite the growing popularity of POC marketing via EHR platforms, this channel remains highly fragmented. For omnichannel marketers, that fragmentation can represent challenges in finding scale, transparency, and uniformity in targeting and performance reporting.

Want to better engage patients with complex diagnoses? Embrace digital.

Partner Content

Want to better engage patients with complex diagnoses? Embrace digital.

Patients often struggle to find specialist care, delaying needed treatment. Digital tools can help.

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.